Excalipoint Therapeutics and DP Technology Partnership | Lucid Diligence Brief
Excalipoint Therapeutics and DP Technology have partnered to develop an agentic…
Servier Completes Edgewise Muscular Dystrophy Acquisition | Lucid Diligence Brief
Servier Completes the Edgewise Muscular Dystrophy Acquisition and Adds…
United Therapeutics’ Thymmune acquisition | Lucid Diligence Brief
United Therapeutics adds Thymmune’s iPSC thymic-cell platform to its…
SERB–Hansa Idefirix Deal | Lucid Diligence Brief
SERB’s Idefirix rights acquisition from Hansa Biopharma sharpens its rare…
Bionyra Pharma Launches With $165M to Advance Immunology Biologics | Lucid Diligence Brief
Bionyra Pharma launched with $165M to advance TL1A, IL-23 and IL-25 biologics…
AbbVie's Apogee Acquisition Valued at $10.9B. | Lucid Diligence Brief
AbbVie’s Apogee deal adds zumilokibart and asthma assets as immunology growth…
Vedana Therapeutics Advances Migraine Antibody Pipeline | Lucid Diligence Brief
Vedana Therapeutics has emerged from stealth with $46 million in Series A…
Lonza Antharis Dual-Payload ADC License | Lucid Diligence Brief
Lonza and Antharis license dual-payload ADC technology for gastrointestinal…
Vaccines Today—June 12, 2026
This weekly update in Vaccines and Immunization highlights key developments…
Lucid Diligence Brief: AlzeCure Pharma Collaboration and Out-Licensing Agreement with Eli Lilly
Lucid Diligence Brief: AlzeCure Pharma Collaboration and Out-Licensing…
Nurix Roche Bexobrutideg Deal | Lucid Diligence Brief
Roche’s collaboration with Nurix turns bexobrutideg into a multi-indication BTK…
Ascidian and Lilly $1.9B Deal for Kidney RNA Editing | Lucid Diligence Brief
Ascidian and Lilly $1.9B collaboration tests whether RNA exon editing can move…